Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Seasonique

- PMLiVE

Opt in or opt out?

Changes to European patent law raise a number of questions for the industry

EU flag

EU launches HIV action plan

Aims to "significantly contribute" to elimination of HIV in EU by 2020

- PMLiVE

Another setback for Teva’s laquinimod in MS

Side effects seen in two late-stage trials but development will continue

Teva Pharma logo

Teva buys into Heptares oral CGRP programme for migraine

Signs$410m alliance for early-stage candidates in potentially-lucrative drug class

Teva Pharma logo

TEVA’s tardive dyskinesia drug wins FDA breakthrough status

SD-809 to be given development incentives

Teva Pharma logo

TEVA buys Mexico’s RIMSA for $2.3bn

Follows acquisition ofAllergan’s generic drugs business

- PMLiVE

IBM teams up with Teva for global eHealth collaboration

Willalso partner with ICON on cancer trials project

- PMLiVE

A Schengen area of healthcare

Moving to a more coordinated and cooperative European response to health threats

- PMLiVE

Pfizer launches first self-injectable contraceptive in UK

New option for female contraception hits UK

Teva Pharma logo

Teva rolls out first migraine patch in US

Delivers alternative treatment option for migraine sufferers

Teva Pharma logo

Teva takes controlling stake in genomics specialist

World’s largest generics firm takes deeper steps into patented medicines development

- PMLiVE

Pfizer links with Synthon on generic Copaxone

US giant looking to grab a share of the copycat market for the MS drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links